Lorena Kuri: BMS made commitments to health equity, clinical trial diversity and addressing the needs of underrepresented populations back in 2020. To do that, we need information, specifically data.
BMS presented trial results from mezigdomide and arlocabtagene autoleucel at EHA 2026. Credit: Tada Images/Shutterstock.com. Bristol Myers Squibb (BMS) has revealed clinical data for two pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results